BRAF and thyroid cancer: Treatment with sorafenib, the MEK inhibitor U0126 and the BRAF‐specific inhibitor PLX4720 did not change the mitochondrial localization or anti‐apoptotic activity of BRAF V600E in thyroid cancer.15